Documentation of the use of Varitect® CP in patients with herpes zoster, the VARIZOSTA study (NIS-022)

Study identification

• EU PAS number:
  EUPAS103611
• Study ID:
  105651
• Official title and acronym:
  Documentation of the use of Varitect® CP in patients with herpes zoster, the VARIZOSTA study (NIS-022)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Assessment of the real-world usage of Varitect CP in patients with HZ. HZ patients, both treated with and without Varitect CP, will be documented in the NIS. Non-interventional, prospective, controlled, multi-center, post-approval study.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Universitätsklinikum Schleswig-Holstein

Klinik für Dermatologie,Allergologie und Venerologie

Study timelines

Date when funding contract was signed

Actual:26/09/2022

Study start date

Planned:31/03/2023

Actual:01/06/2023

Data analysis start date

Planned:30/06/2026

Date of final study report

Planned:31/03/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Biotest AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable